戈利木单抗治疗非感染性葡萄膜炎的疗效：一项符合 PRISMA 原则的系统评价和荟萃分析。
The Efficacy of Golimumab Against Non-Infectious Uveitis: A PRISMA-Compliant Systematic Review and Meta-Analysis.
机构信息
Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Quality Assurance Department, Nippon Ciba Geigy Co, Hyogo, Japan.
出版信息
Ocul Immunol Inflamm. 2023 Jul;31(5):1013-1023. doi: 10.1080/09273948.2022.2081584. Epub 2022 Jun 30.
PURPOSE
In this PRISMA-compliant systematic review and meta-analysis, we aimed to assess the efficacy of golimumab (GOL) against non-infectious uveitis (NIU).
METHODS
We included eight articles in the meta-analysis. The primary outcome was inflammation remission. Secondary outcomes were changes in the number of uveitis relapses/attacks, mean best-corrected visual acuity, central macular thickness, and systemic corticosteroid-sparing effects.
RESULTS
In total, eight case series with 172 patients (43.6% female) were collected. Patients had 75% (95% CI: 56-87%) of remission; 42% (0.12-0.80) of patients showed improved visual acuity. The average central macular thickness decline was 38 μm (-56.51-18.54). The pooled results showed a significant decrease in the use of systemic corticosteroids.
CONCLUSION
This study was limited by the use of non-RCT designs, limited sample sizes for outcomes, and heterogenetic underlying diseases. Our results suggest that GOL is effective against NIU. However, further evidence and analyses are required. (Funding: None; PROSPERO registration: CRD42021266214.).
目的
在这项符合 PRISMA 标准的系统评价和荟萃分析中，我们旨在评估戈利木单抗（GOL）治疗非感染性葡萄膜炎（NIU）的疗效。
方法
我们将 8 篇文章纳入荟萃分析。主要结局是炎症缓解。次要结局是葡萄膜炎复发/发作次数、最佳矫正视力均值、中央黄斑厚度和全身皮质类固醇节省效应的变化。
结果
共收集了 8 项病例系列研究，共 172 例患者（43.6%为女性）。患者的缓解率为 75%（95%CI：56-87%）；42%（0.12-0.80）的患者视力得到改善。平均中央黄斑厚度下降 38 μm（-56.51-18.54）。汇总结果显示，全身皮质类固醇的使用显著减少。
结论
本研究受到非随机对照设计、结局样本量有限以及潜在疾病异质性的限制。我们的结果表明 GOL 对 NIU 有效。然而，还需要更多的证据和分析。（资金来源：无；PROSPERO 注册号：CRD42021266214。）
Zotero 插件